76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm…
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
BAY CITY, Mich., Dec. 04, 2025 (GLOBE NEWSWIRE) -- McLaren Bay Region has equipped its Emergency Department treatment rooms with…
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the…
MUMBAI, India, Nov. 27, 2025 /PRNewswire/ -- In a country with over 1.4 million[i] cases reported annually, with most being…
November 26, 2025 19:00 ET | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27,…